

# Index

- acamprosate, 152
- activities of daily living (ADLs), 108–9
- addiction. *See* substance use
- adjustment disorder with depressed mood, 31
- Adler, Gerald, 83
- admission note, 187, 188, 189
- adulthood
  - Blos, Erikson, and Winnicott perspective on, 166–9
  - definition of, 162–3
  - factors delaying or quickening age of, 163–4
- aggression, traumatic brain injury, 132, 133–5
- agitation management
  - dementia, 107, 114–20, 121
  - mania, 69–70
  - schizophrenia, 2, 3, 18, 19
  - traumatic brain injury, 126–7, 133–6
- akathisia treatment, 16, 17
- alcohol use. *See also* dual diagnosis
  - evaluation, 146–7
  - medical, 148–50
  - management, 150–2
  - physical complications, 150
  - schizophrenia and, 3
  - traumatic brain injury and, 130
  - withdrawal, 144–5, 150–1
  - young adult, 171
- alcohol-related dementia, 112–14
- Alzheimer's dementia, 112–14
  - depression in, 122
  - pharmacologic strategies, 117–18
- amantadine, 16, 17, 133–5
- amisulpride, 10–14
- amitriptyline, 135
- amnesia, posttraumatic, 129
- amphetamine use, 143, 144, 150, 154–5
- anabolic-androgenic steroid (AAS) use, 150, 155–6
- anticholinergics, schizophrenia, 16–18
- anticonvulsants
  - borderline personality disorder, 94, 96–7
  - dementia, 119, 121
  - traumatic brain injury, 133–5
- antidementia drugs, 117–18, 121
- antidepressants
  - anxiety, 153
  - bipolar depression, 49–50
  - borderline personality disorder, 94–5
  - dementia, 119, 120, 121
  - dementia with depression, 122
  - psychotic depression, 49
  - schizoaffective disorder, 21
  - schizophrenia, 17
  - suicide risk management, 20
  - traumatic brain injury, 134, 135
  - unipolar depression, 47–9
  - young adults, 171, 172
- antihistamines, 153
- antipsychotic medication
  - antidepressant interactions with, 17
  - anxiety, 153
  - borderline personality disorder, 94, 95–6
  - dementia, 118–19, 120, 121
  - dual diagnosis, 144–5
  - long-acting depot injections, 16
  - mania, 69–70, 71, 72, 73–4
  - schizoaffective disorder, 21
  - schizophrenia, 4–5, 9–16, 18
  - side effects, 9–14, 15
  - traumatic brain injury and, 126–7, 133–5

Cambridge University Press  
978-1-108-46101-6 — Manual of Inpatient Psychiatry  
Edited by Michael I. Casher, Joshua D. Bess

Index

[More Information](#)

Index | 199

- unipolar depression, 49
- young adults, 171, 172
- anxiety
  - benzodiazepine alternatives for, 153
  - benzodiazepine use with, 152–4
  - substance use with, 146–7
  - traumatic brain injury and, 131–2, 135
- APA Practice Guideline, depression treatment, 47
- aripiprazole
  - borderline personality disorder, 96
  - dementia, 119
  - long-acting depot injections, 16
  - mania, 69–70, 71
  - side effects, 10–14
  - traumatic brain injury and, 133–5
  - unipolar depression, 49
- asenapine, 10–14
- assessment, 190–1, 192
  - suicide risk, 193
- atenolol, 152
- atomoxetine, 135, 155
- attention-deficit/hyperactivity disorder (ADHD), 155
- atypical antipsychotics
  - anxiety, 153
  - dementia, 118–19, 120, 121
  - mania, 69–70, 71, 72
  - schizophrenia, 9–16, 18
  - side effects, 9–14, 15
  - traumatic brain injury and, 133–5
  - unipolar depression, 49
  - young adults, 171
- Beck Depression Inventory (BDI), 31–2
- Behavioral Activity Rating Scale (BARS), 18, 69
- behavioral and psychiatric symptoms of dementia (BPSD), 106–8, 114–15
  - behavioral treatment strategies, 115–17
  - pharmacologic treatment strategies, 117–20, 121
- behavioral management, traumatic brain injury, 132, 133
- benzodiazepine use, 152–4
- benzodiazepines
  - acutely psychotic patient, 2
  - alcohol withdrawal, 150–1
  - borderline personality disorder, 94, 95
  - catatonia, 46–7
  - dementia, 120
  - dual diagnosis, 144–5
  - mania, 69–70, 72
  - schizophrenia, 16–18
  - traumatic brain injury, 126–7, 133–5
- benztropine, 16
  - mania, 69–70
  - schizophrenia, 18
- beta blockers
  - benzodiazepine use management, 152
  - schizophrenia, 16–18
  - traumatic brain injury, 133–5
- biopsychosocial model, 29, 191
- bipolar and related disorder due to another medical condition, 68
- bipolar disorder, 31. *See also* mania
  - depressive phase pharmacologic treatment, 49–50
  - diagnosis, 43, 44
  - electroconvulsive therapy, 50
  - personality disorders with, 74–5, 84
  - psychological issues associated with treatment, 74–5
  - schizophrenia distinction from, 6–8, 65
  - substance use with, 151, 153–4
  - young adult, 169–70
- Blos, Peter, 166–7
- borderline personality disorder (BPD)
  - challenges in working with, 82
  - comorbidity assessment, 87–8
  - coordination with outpatient team, 100–1
  - diagnostic interview, 85–7
  - dissociation relationship, 88–9
  - electroconvulsive therapy, 97
  - etiology, 83–4
  - inpatient compared with outpatient approach to, 89–90, 91

Cambridge University Press  
978-1-108-46101-6 — Manual of Inpatient Psychiatry  
Edited by Michael I. Casher, Joshua D. Bess

Index

[More Information](#)

## 200 | Index

- mania and, 68
- medication, 93–4
  - anxiety medications, 94, 95
  - antidepressants, 94–5
  - antipsychotics, 94, 95–6
  - mood stabilizers/anticonvulsants, 94, 96–7
  - opioid antagonists, 94, 97
- neurobiology, 83–4
- presentation of diagnosis to patient, 99–100
- psychosis relationship, 88
- psychotherapy, 90–2
  - in brief inpatient stay, 92–3
  - reasons for admission, 84–5
  - substance use with, 88, 147–8
  - suicide risk management, 97–9
  - young adult, 170
- botulinum toxin injections (Botox), 35
- breast-feeding, 172
- brexanolone, 52
- brexpiprazole, 10–14, 49
- brief psychotic disorder, 5
- brintellix, 48
- Buie, Daniel, 83
- buprenorphine, 154
- bupropion
  - ADHD, 155
  - borderline personality disorder, 94–5
  - unipolar depression, 47–9
  - young adults, 172
- buspirone, 134, 153
- cannabis use, 150, 155
- carbamazepine
  - borderline personality disorder, 94, 96–7
  - dementia, 119
  - mania, 72, 73
  - schizophrenia, 17
  - traumatic brain injury, 133–5
  - young adults, 172
- cariprazine, 10–14
- catatonia, 45–7
- chemical dependency. *See* substance use
- cholinesterase inhibitors, 117–18, 121
- chronic traumatic encephalopathy (CTE), 136–7
- chronotherapy, 52–3, 76
- ciprofloxacin, 68
- citalopram, 119, 122
- clinical documentation
  - assessment, 190–1, 192
  - suicide, 193
  - characteristics of good, 186–7
  - essential functions of, 185–6
  - medico-legal role of, 192–3
  - notes tailored to specific purposes or audiences, 195
  - readers of, 183, 184
  - reasons for reading, 183–5
  - things not to include, 193–4
  - types of, 187–90, 191
- clozapine
  - mania, 73–4
  - schizophrenia, 14–16, 17–18
  - side effects, 10–14
  - suicide risk management, 20
  - traumatic brain injury, 133–5
- cocaine use, 146, 150, 154–5
- cognitive-behavioral therapy (CBT), 53
- college students, 171, 173–4
- confidentiality, young adults, 174
- co-occurring disorder. *See* dual diagnosis
- coup-contrecoup injury, 128
- dark therapy, 76
- delusion, 1
- delusional disorder, 5
- dementia
  - agitation management, 107, 114–20, 121
  - behavioral and psychiatric symptom treatment, 114–15
  - behavioral strategies, 115–17
  - pharmacologic strategies, 117–20, 121
- consultant role, 111–12
- depression with, 38, 107–8, 120–2

- distinction of various forms, 112–14  
 evaluation  
   general medical, 107, 110–11  
   information gathering, 108–10  
   reasons for admission, 106–8  
   reversible causes, 107
- depression  
   admission interview, 31–3, 36  
   catatonia relationship, 45–7  
   dementia with, 38, 107–8, 120–2  
   diagnosis, 31–3  
   electroconvulsive therapy, 28, 49, 50  
   general issues in initial evaluation,  
     29–30  
   history taking, 36–7  
   imaging studies, 37–8  
   interview style, 36  
   involuntary hospitalizations, 30  
   medical causes of, 37–8  
   melancholic, 33, 34, 35  
   newer treatments for, 51–3  
   pharmacologic treatment  
     bipolar depression, 49–50  
     unipolar depression, 47–9  
   psychotherapeutic approaches, 53–4  
   psychotic, 43–4, 49  
   reasons for hospitalization, 28–9  
   schizophrenia with, 17  
   substance use with, 146–7, 151  
   suicide risk evaluation, 38–42  
   symptoms, 31–2, 33  
   traumatic brain injury and, 131, 135  
   treatment-resistant  
     assessment, 42–4, 45  
     correlates of treatment  
       resistance, 45  
   women, 34–6  
   young adult, 168, 169–70
- desipramine, 48, 135
- detoxification, alcohol, 144–5, 150–1
- dextroamphetamine, 155
- diagnosis  
   bipolar disorder, 43, 44  
   borderline personality disorder, 85–7  
   depression, 31–3  
   dual diagnosis disorders, 145–7  
   mania, 63–5  
   schizophrenia, 3–5, 6–8  
   dialectical-behavioral therapy (DBT)  
     borderline personality disorder, 89–92  
     depression, 41  
   DICE method, 115–17  
   diphenhydramine, 16, 17, 18  
   discharge summary, 187, 188–90, 191  
   dissociation, 88–9  
   disulfiram, 152  
   documentation. *See* clinical  
     documentation  
   dual diagnosis. *See also* substance use  
     evaluation, 145–7  
     medical, 148–50  
     issues often missed in, 144–5  
   management  
     alcohol dependence, 150–2  
     benzodiazepine use, 152–4  
     cannabis use, 155  
     cocaine or amphetamine use,  
       154–5  
     opiate dependence, 154  
     steroid use, 155–6  
   motivational interviewing, 148, 149  
   personality disorder/substance use  
     disorder, 147–8  
   reasons for admission, 142–4  
   terminology, 142  
   treatment hints, 156  
   young adult, 171
- dysphoric mania, 63
- electroconvulsive therapy (ECT)  
   borderline personality disorder, 97  
   catatonia, 46–7  
   dementia with depression, 121  
   depression, 28, 49, 50  
   mania, 73–4  
   traumatic brain injury, 135
- electronic health records (EHRs), 183,  
 186–7
- Erikson, Erik, 167
- escitalopram, 47, 122

**202 | Index**

- esketamine, 51–2
- extra pyramidal symptoms (EPS), 9–14, 171
- family history, schizophrenia or bipolar disorder, 6–8
- fear management, schizophrenia, 2, 3
- fluoxetine, 17, 49, 50
- fluphenazine decanoate, 16
- folate, 150–1
- formulation, 190–1, 192
- frontal lobe injuries, 127, 132
- frontotemporal dementia, 112–14
- gabapentin
  - anxiety, 153
  - benzodiazepine use management, 152
  - borderline personality disorder, 95
- Glasgow Coma Scale (GCS), 129
- good psychiatric management (GPM), 89–90, 91–3
- Gunderson, John, 83
- hallucination, 1
- hallucinogen use, 150
- haloperidol
  - mania, 69–70, 71
  - schizophrenia, 9–14, 16, 18
- haloperidol decanoate, 16
- Hamilton Rating Scale for Depression (HAM-D), 31–2
- head trauma. *See* traumatic brain injury
- heroin use, 146
- history taking
  - dementia, 108–10
  - depression, 36–7
  - dual diagnosis, 145–7
  - mania, 66–7
  - psychosis, 3–5, 6–8
  - traumatic brain injury, 130–1
- Huntington's disease-associated dementia, 112–14
- iloperidone, 10–14
- imaging studies
  - borderline personality disorder, 83–4
  - dementia, 110–11
  - depression, 37–8
  - mania, 68
  - schizophrenia, 5–6, 7
- impression, 190–1, 192
- inhalant use, 150
- instrumental activities of daily living (IADLs), 108–9
- interpersonal therapy (IPT), 53
- involuntary hospitalization
  - depression, 30
  - young adults, 174
- Kernberg, Otto, 83
- ketamine, 51–2
- Kraepelin's mood states, 64–5
- lamotrigine
  - bipolar depression, 50
  - borderline personality disorder, 96–7
  - traumatic brain injury, 133–5
  - young adults, 172
- levomilnacipran, 48
- Lewy body dementia, 112–14, 117–18
- light therapy, 52–3, 76
- lithium
  - bipolar depression, 50
  - borderline personality disorder, 94, 96–7
  - mania, 71, 72–3
  - schizophrenia, 17
  - traumatic brain injury, 133–5
  - unipolar depression, 49
  - young adults, 172
- lorazepam
  - benzodiazepine use management, 152
  - dementia, 120
  - mania, 69–70
  - schizophrenia, 2, 18
- loss of consciousness (LOC)
  - duration, 129
- L-triiodothyronine, 49
- lurasidone, 50

- major depression
  - diagnosis, 31
  - young adult, 169–70
- major depression with psychotic features, 43–4, 49
- major neurocognitive disorder. *See* dementia
- malpractice suits, clinical documentation in, 192–3
- mania
  - approach to acutely manic patient assessment, 66–8
  - management, 69–70
  - comorbid conditions, 67–8
  - diagnosis, 63–5
  - history taking, 66–7
  - imaging studies, 68
  - issues with manic states, 63–5
  - light therapy, 76
  - management priorities, 69–70
  - mixed state, 63–5
  - nonpharmacologic treatment, 75–6
  - pharmacologic treatment
    - acute management, 69–70
    - long-term strategies, 70–4, 75
  - psychological issues associated with treatment, 74–5
  - psychosis distinction from, 6–8, 65
  - reasons for hospitalization, 65–6
  - traumatic brain injury and, 131
  - young adult, 169–70
- melancholic depression, 33, 34, 35
- mentalization, 91
- metabolic side effects, atypical
  - antipsychotics, 9–14, 15
- methamphetamine use, 143, 144
- methylphenidate, 155
- mild traumatic brain injury (mTBI), 127–8, 136–7
- mini-mental status exam (MMSE), 109–10
- mirtazapine, 17
  - anxiety, 153
  - dementia with depression, 122
  - schizophrenia, 17
  - traumatic brain injury, 135
  - unipolar depression, 47–9
- monoamine oxidase inhibitors (MAOIs)
  - borderline personality disorder, 94–5
  - traumatic brain injury, 135
  - unipolar depression, 48–9
- Montgomery-Asberg Depression Rating Scale (MADRS), 31–2
- Montreal Cognitive Assessment (MoCA), 109–10
- mood disorder due to a general medical condition, 31
- mood disorders. *See also* bipolar disorder; depression
  - psychosis with, 17, 20–1
  - young adult, 169–70
- mood stabilizers
  - borderline personality disorder, 94, 96–7
  - dementia, 119
  - mania, 71, 72–3
  - schizoaffective disorder, 21
  - schizophrenia, 17
  - traumatic brain injury, 133–5
  - young adults, 172
- motivational interviewing, 148, 149
- naltrexone, 94, 97, 152
- negative symptoms, schizophrenia, 2
- neuroimaging studies. *See* imaging studies
- N-methyl-D-aspartate (NMDA) receptor antagonists, 51–2
- nortriptyline, 48, 135
- olanzapine
  - bipolar depression, 50
  - borderline personality disorder, 96
  - dementia, 119, 120
  - long-acting depot injections, 16
  - mania, 69–70, 71
  - psychotic depression, 49
  - schizoaffective disorder, 21
  - schizophrenia, 18
  - side effects, 10–14

Cambridge University Press  
978-1-108-46101-6 — Manual of Inpatient Psychiatry  
Edited by Michael I. Casher, Joshua D. Bess

Index

[More Information](#)

## 204 | Index

- omega sign, 35
- opiate/opioid use
  - borderline personality disorder and, 88
  - dual diagnosis, 143, 144, 145, 146–7
  - management, 154
  - physical complications, 150
- opioid antagonists, 94, 97
- organic mood disorder, 68
- oxcarbazepine
  - dementia, 119
  - mania, 72, 73–4
  - young adults, 172
- paliperidone, 10–14, 16
- pancreatic cancer, 37
- Parkinson's dementia, 112–14
- paroxetine, 17, 122
- perimenopausal depression, 34–6
- perphenazine, 14, 49
- personality disorders. *See also* borderline personality disorder
  - bipolar disorder with, 74–5, 84
  - substance use disorder with, 147–8
- phenobarbital, 152
- pimavanserin, 112–13
- poor mental health associated with
  - drinking (PMHD), 171
- Positive and Negative Syndrome Scale (PANSS), 18, 69
- positive symptoms, schizophrenia, 1–2
- postconcussive syndrome (PCS), 127–8, 136–7
- postpartum depression, 34–6, 52, 168
- postpartum psychosis, 5
- posttraumatic amnesia, 129
- posttraumatic stress disorder (PTSD)
  - borderline personality disorder and, 84
  - substance use with, 146–7
  - traumatic brain injury and, 131–2
- pregabalin, 153
- pregnancy
  - depression considerations, 34–6
  - young adult, 168, 172
- premenstrual dysphoric disorder, 34–6
- premenstrual syndrome, 34–6
- prescription drug overuse, 146
- progress note, 187, 188, 190
- propranolol, 133–5, 152
- pseudodementia, 38, 120–2
- psychoeducation
  - depression, 29, 53–4
  - schizophrenia, 4–5
- psychosis. *See also* schizophrenia
  - borderline personality disorder relationship, 88
  - diagnoses other than schizophrenia, 5
  - history taking, 3–5, 6–8
  - initial workup, 5–6, 7
  - interaction with acutely psychotic patient, 2, 3
  - mania distinction from, 6–8, 65
  - mood disorders with, 17, 20–1
  - symptoms, 1–2
  - traumatic brain injury and, 126, 131
- psychotherapy
  - borderline personality disorder, 90–3
  - depression, 53–4
- psychotic depression, 43–4, 49
- psychotic disorder due to medical illness, 5
- quetiapine
  - benzodiazepine use management, 152
  - bipolar depression, 50
  - borderline personality disorder, 96
  - dementia, 119
  - mania, 71
  - side effects, 10–14
  - unipolar depression, 49
- restraint note, 187–8
- risperidone
  - borderline personality disorder, 96
  - dementia, 119
  - long-acting depot injections, 16
  - mania, 69–70, 71
  - side effects, 10–14
- rivastigmine, 117–18

- schizoaffective disorder, 5, 20–1
- schizophrenia
- agitation management, 2, 3, 18, 19
  - antipsychotic medication, 4–5
    - agitation management, 18
    - factors involved in selection, 9–16
  - depression with, 17
  - diagnosis, 3–5, 6–8
  - factors to consider on admission, 8–9
  - history taking, 3–5, 6–8
  - initial workup, 5–6, 7
  - interaction with acutely psychotic patient, 2, 3
  - mania distinction from, 6–8, 65
  - medication regimens other than antipsychotics, 16–18
  - negative symptoms, 2
  - positive symptoms, 1–2
  - reasons for admission, 1–2
  - schizoaffective disorder compared with, 20–1
  - substance use with, 3, 4–5, 151, 153–4, 155
  - suicide risk management, 18–20
  - treatment plan, 21–3
  - treatment-refractory patients, 16–18
  - young adult, 170–1, 177
- second generation antipsychotics. *See* atypical antipsychotics
- secondary mania, 68
- sedative use, 150, 152–4
- sedatives. *See also* benzodiazepines
- dual diagnosis, 144–5
- selective serotonin reuptake inhibitors (SSRIs)
- anxiety, 153
  - borderline personality disorder, 94–5
  - dementia, 119, 120
  - dementia with depression, 122
  - schizophrenia, 17
  - traumatic brain injury, 134, 135
  - unipolar depression, 47, 48–9
  - young adults, 172
- self-harm, 97–9, 177
- serotonin and norepinephrine reuptake inhibitors (SNRIs)
- anxiety, 153
  - borderline personality disorder, 94
  - traumatic brain injury, 134, 135
  - unipolar depression, 48–9
  - young adults, 172
- sertraline
- alcohol use, 152
  - dementia, 119
  - dementia with depression, 122
  - psychotic depression, 49
  - unipolar depression, 47
- shared delusional disorder, 5
- steroid use, 150, 155–6
- stimulant use, 143, 144, 150, 154–5
- stimulants, traumatic brain injury, 134, 135
- substance use
- borderline personality disorder and, 88, 147–8
  - depression with, 146–7, 151
  - evaluation, dual diagnosis, 145–7, 148–50
  - issues often missed in, 144–5
  - management
    - alcohol dependence, 150–2
    - benzodiazepine use, 152–4
    - cannabis use, 155
    - cocaine or amphetamine use, 154–5
    - opiate dependence, 154
    - steroid use, 155–6
  - mania and, 67–8
  - motivational interviewing, dual diagnosis, 148, 149
  - personality disorders with, 147–8
  - physical complications, 150
  - reasons for admission, dual diagnosis, 142–4
  - schizophrenia and, 3, 4–5, 151, 153–4, 155
  - suicide risk, 144
  - terminology, 142
  - traumatic brain injury and, 130, 137
  - young adult, 171, 177



- substance-induced mood disorder, 31  
 substance-induced psychotic disorder, 5  
 suicide risk  
     assessment, 193  
     borderline personality disorder, 84–5, 97–9  
     depression, 38–42  
     schizophrenia, 18–20  
     substance use and, 144  
     young adults, 175–7
- temazepam, 70  
 temporal lobe injuries, 127  
 Texas Medication Algorithm Project (TMAP), 47  
 thiamine, 150–1  
 thought disorder, 1  
 thyroxine, 49  
 topiramate  
     borderline personality disorder, 94, 96–7  
     mania, 72, 73–4  
     young adults, 172  
 transcranial magnetic stimulation (TMS), 51  
 traumatic brain injury (TBI)  
     behavioral management, 132, 133  
     brain disruptions in, 128  
     evaluation, 130–1  
     factors in presentation and prognosis, 129–30  
     medication, 133–6  
     postconcussion syndrome and chronic traumatic encephalopathy, 136–7  
     pre-injury psychiatric disorder with, 127–8, 129–30  
     pros and cons of admission, 132, 133  
     relevance to inpatient work, 126–8  
     severity, 129  
     substance use and, 130, 137  
     syndromes treated on inpatient unit, 131–2  
 trazodone, 17, 134, 135  
 treatment-refractory schizophrenia, 16–18  
 treatment-resistant depression (TRD), 42–4, 45  
 tricyclic antidepressants (TCAs)  
     anxiety, 153  
     borderline personality disorder, 94–5  
     psychotic depression, 49  
     traumatic brain injury, 134, 135  
     unipolar depression, 48–9  
 trihexylphenidyl, 16
- University of Michigan Inpatient Psychiatry Agitation Protocol, 19  
 urine drug screen (UDS), 148–9
- valproate  
     borderline personality disorder, 94, 96–7  
     dementia, 119  
     mania, 71, 72, 73  
     schizoaffective disorder, 21  
     schizophrenia, 17  
     traumatic brain injury, 133–5  
     young adults, 172  
 vascular dementia, 112–14  
 venlafaxine, 47–8  
 vilazodone, 48  
 violence risk, young adults, 177
- weight gain  
     atypical antipsychotics, 9–14, 15  
     young adults, 172  
 wellness, in schizophrenia  
     treatment, 22–3  
 Wernicke–Korsakoff syndrome, 112–14  
 Winnicott, DW, 168–9  
 withdrawal, alcohol, 144–5, 150–1  
 women, depression considerations, 34–6
- young adults  
     Blos, Erikson, and Winnicott  
         perspective on, 166–9  
     college students, 171, 173–4  
     common psychiatric diagnoses, 169–71  
     definition of, 162–3

Cambridge University Press  
978-1-108-46101-6 — Manual of Inpatient Psychiatry  
Edited by Michael I. Casher , Joshua D. Bess  
Index  
[More Information](#)

	Index	207
factors delaying or quickening age of adulthood, 163–4	violence risk factors, 177	
hints for connecting with, 167	Young Mania Rating Scale (YMRS), 67	
legal issues, 174		
medications, 171–3	ziprasidone	
problems associated with	borderline personality disorder, 96	
hospitalization, 164–6, 167	dementia, 120	
pros and cons of mixing younger and older patients, 174–5	mania, 69–70	
suicide risk evaluation and management, 175–7	schizophrenia, 18	
tasks of, 163	side effects, 10–14	
	traumatic brain injury and, 133–5	
	zolpidem, 70	
	zotepine, 10–14	